GUANIDINE THIOCYANATE

US Previously Marketed

First approved in 1939

Details

Stereochemistry	ACHIRAL
Molecular Formula	CH5N3.CHNS
Molecular Weight	118.161
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

SC#N.NC(N)=N

InChI

InChIKey=ZJYYHGLJYGJLLN-UHFFFAOYSA-N

InChI=1S/CH5N3.CHNS/c2-1(3)4;2-1-3/h(H5,2,3,4);3H

HIDE SMILES / InChI

Molecular Formula	CHNS
Molecular Weight	59.09
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH5N3
Molecular Weight	59.0705
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated potassium channel 17 Target ID: CHEMBL2362996 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21926190	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Eaton-Lambert syndrome 5 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	Palliative		Approved 8583	GUANIDINE HYDROCHLORIDE Approved Use Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis. Launch Date 1939

PubMed

Title	Date	PubMed
Selective substrates for non-neuronal monoamine transporters.	1999 Jul	10385678
Presynaptic imidazoline receptors. New developments in characterization and classification.	1999 Jun 21	10415912
[The study of the Ca2+ role in cytotoxic response of human cells in culture to the action of xenobiotics].	2000	10752119
The picornavirus replication inhibitors HBB and guanidine in the echovirus-9 system: the significance of viral protein 2C.	2000 Apr	10725414
Dihydrofolate reductase from Thermotoga maritima.	2001	11265474
Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 1. Conversion of 5-substituent on oxazolidinone.	2001 Apr	11310656
Total chemical synthesis of human matrix Gla protein.	2001 Apr	11274477
Strain-specified relative conformational stability of the scrapie prion protein.	2001 Apr	11274476
High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin.	2001 Apr	11259312
Species-specific PCR for the identification of ovine, porcine and chicken species in meta and bone meal (MBM).	2001 Feb	11284433
Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes.	2001 Feb	11276368
Metric engineering of soft molecular host frameworks.	2001 Feb	11263869
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.	2001 Feb	11168991
Structure of an intermediate in the unfolding of creatine kinase.	2001 Feb 1	11119651
Equilibrium unfolding of Bombyx mori glycyl-tRNA synthetase.	2001 Feb 9	11056158
Dichlorobis(glycocyamine-O)copper(II).	2001 Jan	11173378
Phaeochromocytoma: an unusual cause of hypertension in pregnancy.	2001 Jan	11167434
The relationship between visible intracellular aggregates that appear after overexpression of Sup35 and the yeast prion-like elements [PSI(+)] and [PIN(+)].	2001 Jan	11123686
Folding-unfolding of goat alpha-lactalbumin studied by stopped-flow circular dichroism and molecular dynamics simulations.	2001 Jan 1	11093260
Limited tryptic hydrolysis of pea legumin: molecular mass and conformational stability of legumin-T.	2001 Jan 10	11164235
Hydrophobic core malleability of a de novo designed three-helix bundle protein.	2001 Jan 12	11124911
Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains.	2001 Jan 12	11050093
Disulfide-dependent folding and export of Escherichia coli DsbC.	2001 Jan 12	11042167
Conformational origin of the aggregation of recombinant human factor VIII.	2001 Jan 16	11148054
The PD...(D/E)XK motif in restriction enzymes: a link between function and conformation.	2001 Jan 16	11148032
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp.	2001 Jan 23	11170394
Distributions of intramolecular distances in the reduced and denatured states of bovine pancreatic ribonuclease A. Folding initiation structures in the C-terminal portions of the reduced protein.	2001 Jan 9	11141061
[Antibody avidity: use for the diagnosis of HIV early infection].	2001 Jan-Feb	11174099
A rigid linker-scaffold for solid-phase synthesis of dimeric pharmacophores.	2001 Jan-Feb	11148071
Protein compactness measured by fluorescence resonance energy transfer. Human carbonic anhydrase ii is considerably expanded by the interaction of GroEL.	2001 Jun 15	11278767
alpha Arg-237 in Methylophilus methylotrophus (sp. W3A1) electron-transferring flavoprotein affords approximately 200-millivolt stabilization of the FAD anionic semiquinone and a kinetic block on full reduction to the dihydroquinone.	2001 Jun 8	11285259
Elucidation of a [4Fe-4S] cluster degradation pathway: rapid kinetic studies of the degradation of Chromatium vinosum HiPIP.	2001 Mar	11315562
Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride.	2001 Mar	11274595
Characterization of carbonic anhydrase from Neisseria gonorrhoeae.	2001 Mar	11248679
Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release.	2001 Mar	11222743
Cutinase unfolding and stabilization by trehalose and mannosylglycerate.	2001 Mar 1	11170208
Major differences in stability and dimerization properties of two chimeric mutants of human stefins.	2001 Mar 1	11170205
The synthesis of beta-peptides containing guanidino groups.	2001 Mar 12	11266170
Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic.	2001 Mar 15	11277694
Structural alterations and inhibition of unisite and multisite ATP hydrolysis in soluble mitochondrial F1 by guanidinium chloride.	2001 Mar 20	11258961
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.	2001 Mar 30	11266439
Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism.	2001 Mar 30	11124964
The structure of denatured alpha-lactalbumin elucidated by the technique of disulfide scrambling: fractionation of conformational isomers of alpha-lactalbumin.	2001 Mar 30	11118458
Cofactor-induced refolding: refolding of molten globule carbonic anhydrase induced by Zn(II) and Co(II).	2001 Mar 6	11258876
Osmolytes protect mitochondrial F(0)F(1)-ATPase complex against pressure inactivation.	2001 Mar 9	11257519
The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase.	2001 Mar 9	11092881
Proton and metal ion-dependent assembly of a model diiron protein.	2001 May	11316876
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.	2001 May 15	11322922

Patents

Sample Use Guides

In Vivo Use Guide

Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.

Route of Administration: Oral

In Vitro Use Guide

Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:52:28 GMT 2025` Edited by `admin` on `Mon Mar 31 19:52:28 GMT 2025`
Record UNII	GCA2EU297U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUFFER AVL

Preferred Name

English

GUANIDINE THIOCYANATE

Common Name

English

GUANIDINIUM ISOTHIOCYANATE

Systematic Name

English

GUANIDINE ISOTHIOCYANATE

Systematic Name

English

GUANIDINIUM THIOCYANATE

Systematic Name

English

NSC-2119

Code

English

Code System Code Type Description

NSC

2119